Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Subjects
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This study will assess the pharmacokinetics of RLX030 during and after administration in
subjects with mild to severe hepatic impairment and matched healthy control subjects.
20 to 24 patients and 20 to 24 healthy subjects will be enrolled.